Diagnostic Center | June 14, 2024
USFDA approves expanded age indication for GSK’s RSV vaccine ‘Arexvy’
Over 13 million US adults aged 50-59 years have a medical condition that increases their risk of severe RSV outcomes
Over 13 million US adults aged 50-59 years have a medical condition that increases their risk of severe RSV outcomes
The Gavi Board today approved the Vaccine Alliance's strategy for the five-year period running from 2026 to 2030
The cancer screening and awareness camp will run for four months in the Mira Bhayander Region, benefiting approximately 5,000 police personnel
mRESVIA is Moderna's second approved product and the only RSV vaccine available in single-dose pre-filled syringes
SUPERNOVA is a large Phase III global trial providing the only efficacy data in immunocompromised patients
Aptar Closures’ E-Disc Top securely protects against in-transit leakage while eliminating the need for liners and extra shipping preparation fees
Sales reflect continued strong growth in oncology and vaccines
Approval from Colombia's INVIMA will accelerate growth in Colombia, by registering our product and getting regular supplies
NexGard Spectra is a soft, flavourful monthly chew that kills fleas before they can lay eggs
Submission based on results from pivotal phase III trial showing all primary endpoints met
Subscribe To Our Newsletter & Stay Updated
